GRI Bio, Inc. (GRI)
NASDAQ: GRI · Real-Time Price · USD
1.700
+0.230 (15.65%)
At close: Aug 10, 2026, 4:00 PM EDT
1.830
+0.130 (7.65%)
After-hours: Aug 10, 2026, 7:59 PM EDT
GRI Bio Employees
GRI Bio had 4 employees as of December 31, 2025. The number of employees did not change compared to the previous year.
Employees
4
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$2,727,000
Market Cap
3.01M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 4 | 0 | - | 3 | 1 |
| Dec 31, 2024 | 4 | 0 | - | 3 | 1 |
| Dec 31, 2023 | 4 | 3 | 300.00% | 4 | 0 |
| Dec 31, 2022 | 1 | - | - | 1 | 0 |
Related Stocks
| Company Name | Employees |
|---|---|
| Virax Biolabs Group | 26 |
| Moleculin Biotech | 17 |
| Azitra | 13 |
| Decoy Therapeutics | 11 |
| Artelo Biosciences | 7 |
| Jupiter Neurosciences | 5 |
| CDT Equity | 4 |
| Oragenics | 3 |
GRI News
- 7 weeks ago - GRI Bio announces U.S. FDA granted ODD to GRI-0621 - TheFly
- 7 weeks ago - GRI Bio Secures FDA Orphan Drug Designation for GRI-0621 (Tazarotene) in Idiopathic Pulmonary Fibrosis - GlobeNewsWire
- 7 weeks ago - GRI Bio granted FDA orphan designation for tazarotene - TheFly
- 3 months ago - GRI Bio to Present at A.G.P.'s Annual Healthcare Company Showcase - GlobeNewsWire
- 3 months ago - GRI Bio Reports First Quarter 2026 Financial Results, New Data Reinforcing Differentiated Profile of GRI-0621 in Idiopathic Pulmonary Fibrosis and Highlights Continued Advancement of Differentiated Immune-Modulating Pipeline - GlobeNewsWire
- 3 months ago - GRI Bio Quarterly report: Q1 2026 - Filings
- 3 months ago - GRI Bio Earnings release: Q1 2026 - Filings
- 4 months ago - GRI Bio receives UAE patent allowance for inflammatory disease treatments - TheFly